{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T11:43:55Z","timestamp":1776512635437,"version":"3.51.2"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"am","delay-in-days":321,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.ygyno.2023.02.003","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T21:57:36Z","timestamp":1676584656000},"page":"23-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial"],"prefix":"10.1016","volume":"171","author":[{"given":"Aaron M.","family":"Praiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexia","family":"Iasonos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lea","family":"Moukarzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Dessources","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krysten","family":"Soldan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katy","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara","family":"Long Roche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ginger J.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany","family":"Troso-Sandoval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William P.","family":"Tew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel N.","family":"Grisham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis S.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roisin E.","family":"O'Cearbhaill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Zivanovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2023.02.003_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.ygyno.2023.02.003_bb0010","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","article-title":"Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Shi","year":"2021","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2023.02.003_bb0015","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.ygyno.2023.02.003_bb0020","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of Cytoreductive surgery for relapsed ovarian Cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.ygyno.2023.02.003_bb0025","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary surgical Cytoreduction for recurrent ovarian Cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.ygyno.2023.02.003_bb0030","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.21.00605","article-title":"Secondary Cytoreduction and carboplatin Hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian Cancer: an MSK team ovary phase II study","volume":"39","author":"Zivanovic","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2023.02.003_bb0035","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian Cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ygyno.2023.02.003_bb0045","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ygyno.2016.11.022","article-title":"Chemotherapy delay after primary debulking surgery for ovarian cancer","volume":"144","author":"Seagle","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2023.02.003_bb0050","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ygyno.2016.09.004","article-title":"Preoperative predictors of delay in initiation of adjuvant chemotherapy in patients undergoing primary debulking surgery for ovarian cancer","volume":"143","author":"Singh","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2023.02.003_bb0060","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1245\/s10434-014-4141-4","article-title":"Development and assessment of memorial Sloan Kettering Cancer Center\u2019s surgical secondary events grading system","volume":"22","author":"Strong","year":"2015","journal-title":"Ann. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2023.02.003_bb0065","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2023.02.003_bb0070","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2021.32.e20","article-title":"The role of secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer: what do the trials tell us?","volume":"32","author":"Coleman","year":"2021","journal-title":"J. Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2023.02.003_bb0075","doi-asserted-by":"crossref","first-page":"510","DOI":"10.21037\/atm-20-4690","article-title":"Update on the secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a narrative review","volume":"9","author":"Conte","year":"2021","journal-title":"Ann Transl Med"},{"issue":"6","key":"10.1016\/j.ygyno.2023.02.003_bb0080","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11912-012-0260-x","article-title":"Surgery for relapsed ovarian cancer: when should it be offered?","volume":"14","author":"Harter","year":"2012","journal-title":"Curr. Oncol. Rep."},{"issue":"6","key":"10.1016\/j.ygyno.2023.02.003_bb0085","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1245\/s10434-020-09226-7","article-title":"The role of secondary Cytoreductive surgery in recurrent ovarian Cancer: a systematic review and Meta-analysis","volume":"28","author":"Marchetti","year":"2021","journal-title":"Ann. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2023.02.003_bb0090","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ygyno.2021.10.008","article-title":"Secondary cytoreductive surgery for recurrent ovarian cancer: an SGO clinical practice statement","volume":"163","author":"Harrison","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2023.02.003_bb0100","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2023.02.003_bb0105","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","article-title":"Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the multicenter intergroup study DESKTOP II. A project of the AGO Kommission OVAR, AGO study group, NOGGO, AGO-Austria, and MITO","volume":"21","author":"Harter","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2023.02.003_bb0110","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1245\/s10434-011-1873-2","article-title":"A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection","volume":"19","author":"Tian","year":"2012","journal-title":"Ann. Surg. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2023.02.003_bb0115","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2217\/WHE.11.52","article-title":"Surgery for recurrent ovarian cancer","volume":"7","author":"Heitz","year":"2011","journal-title":"Womens Health (Lond)"},{"issue":"4","key":"10.1016\/j.ygyno.2023.02.003_bb0120","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000445180","article-title":"Introducing Hyperthermic intraperitoneal chemotherapy into gynecological oncology practice - feasibility and safety considerations: single-center experience","volume":"39","author":"Abramian","year":"2016","journal-title":"Oncol Res Treat"},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2023.02.003_bb0125","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.21037\/jgo-20-274","article-title":"Narrative review of cytoreductive surgery and intraperitoneal chemotherapy for peritoneal metastases in ovarian cancer","volume":"12","author":"Boerner","year":"2021","journal-title":"J Gastrointest Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2023.02.003_bb0130","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ygyno.2020.06.487","article-title":"A guide to establishing a hyperthermic intraperitoneal chemotherapy program in gynecologic oncology","volume":"158","author":"Chambers","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2023.02.003_bb0135","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/02656736.2017.1283066","article-title":"Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer","volume":"33","author":"Cowan","year":"2017","journal-title":"Int. J. Hyperth."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823000574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823000574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:51:15Z","timestamp":1715820675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825823000574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":24,"alternative-id":["S0090825823000574"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.02.003","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}